For example, the acetylation status of mTOR targets can alter energy metabolism and redox balance during heart failure, while deacetylation therapies targeting the SIRT1-mTOR axis have shown potential in alleviating diabetic cardiomyopathy (173, 174). Here, MTOR is linked to diabetic cardiomyopathy.